Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects.

Abstract:

BACKGROUND AND OBJECTIVE:Following oral administration of abiraterone acetate, the parent compound abiraterone acetate is rapidly metabolized to abiraterone. To our knowledge, bioanalytical methods to date have not been able to detect the parent compound in human plasma, and bioassay was only performed on the metabolite. A highly sensitive bioanalytical method was developed and validated to measure plasma concentrations of the parent compound. In this study, both analytes were assayed and used to evaluate the full pharmacokinetic profile of abiraterone acetate tablets. METHODS:This was an open-label, single-dose, one-period, one-treatment, pharmacokinetic study performed in 18 healthy subjects. Each subject was administered four tablets (corresponding to a total dose of 1000 mg) of abiraterone acetate. Blood samples for pharmacokinetic analysis were collected up to 60 h post-dose. Subjects' plasma concentrations for abiraterone acetate were assayed using highly sensitive validated bioanalytical methods with a lower limit of quantitation (LLOQ) of 0.5 pg/ml for abiraterone acetate and 0.1 ng/ml for abiraterone. Safety assessments were performed throughout the study. RESULTS:The pharmacokinetic results for abiraterone acetate showed a mean for the maximum plasma concentration (Cmax) of 54.67 ± 68.30 pg/ml, and a median time to maximum concentrations (tmax) of 5.53 h (range 2.67-35.00 h). The means for area under the concentration-time curve (AUC) from time 0 h to infinity (AUCinf) and AUC from time zero h to the time of the last measurable abiraterone acetate concentrations (AUCt) were 386.13 ± 266.80 pg·h/ml and 460.07 ± 378.78 pg·h/ml, respectively. The apparent elimination half-life (t1/2) showed a mean of 8.98 ± 3.92 h. None of the adverse events that affected three subjects (16.7%) were related to the study drug. CONCLUSION:The ability to detect the low plasma abiraterone acetate concentrations, in addition to abiraterone, resulted in a complete characterization of the pharmacokinetics of abiraterone acetate that was not possible with other analytical methods that only measured the metabolite. The development of new bioanalytical methods such as these will allow for a more thorough understanding of the pharmacokinetics of abiraterone acetate, and this, in turn, can have an impact on both future examinations into abiraterone acetate pharmacokinetic behaviour and the evaluation of its generic formulations.

journal_name

Clin Drug Investig

authors

Bouhajib M,Tayab Z

doi

10.1007/s40261-019-00752-1

subject

Has Abstract

pub_date

2019-03-01 00:00:00

pages

309-317

issue

3

eissn

1173-2563

issn

1179-1918

pii

10.1007/s40261-019-00752-1

journal_volume

39

pub_type

临床试验,杂志文章
  • Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.

    abstract:BACKGROUND AND OBJECTIVE:Icosapent ethyl is a high-purity prescription form of eicosapentaenoic acid ethyl ester approved as an adjunct to diet to reduce triglyceride levels in adult patients with triglyceride levels ≥500 mg/dL (≥5.65 mmol/L). The objective of this open-label, drug-drug interaction study was to examine...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-014-0252-8

    authors: Braeckman RA,Stirtan WG,Soni PN

    更新日期:2015-01-01 00:00:00

  • Effect of adverse drug reactions on length of stay in intensive care units.

    abstract::The objective of the present study was to determine the frequency of adverse drug reactions (ADRs) in intensive care units (ICUs) and to evaluate their effect on the length of stay. We performed a prospective study to detect ADRs in 420 patients hospitalised in 10 predetermined beds in the ICU of our hospital between ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199815040-00011

    authors: Vargas E,Simón J,Martin JC,Puerro M,Gonzalez-Callejo MA,Jaime M,Gomez-Mayoral B,Duque F,Gomez-Delgado A,Moreno A

    更新日期:1998-01-01 00:00:00

  • Effects of a Novel Aldose Reductase Inhibitor, Fidarestat (SNK-860), on Vibration Perception Threshold and Subjective Symptoms in Patients with Diabetic Polyneuropathy : An Open-Label Pilot Study.

    abstract:OBJECTIVE:To evaluate the effects of fidarestat (SNK-860) on vibration perception threshold, as measured by C64 quantitative tuning fork (64Hz) analysis, as well as its effects on subjective symptoms in patients with diabetic polyneuro-pathy. DESIGN AND SETTING:Open-label, prospective study conducted at 12 hospitals i...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200424110-00006

    authors: Hotta N,Yasuda K,Sumita Y,Sano T,Kakuta H,Nagashima M,Hayashi Y,Yamamoto M,Wakao T,Okuyama M,Kobayashi M,Mori K

    更新日期:2004-01-01 00:00:00

  • Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.

    abstract:BACKGROUND AND OBJECTIVE:Interferon-alpha treatment is associated with a large number of adverse effects. Depressive symptoms are not unexpected, and potentially dangerous psychiatric adverse effects can induce life-threatening conditions. We compared the incidence of depressive symptoms in patients with chronic hepati...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/00044011-200626110-00005

    authors: Neri S,Pulvirenti D,Bertino G

    更新日期:2006-01-01 00:00:00

  • High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease.

    abstract:OBJECTIVE:To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD). DESIGN AND PATIENTS:Randomised, double-blind, double-dummy, placebo-controlled study in 123 patients experiencing an acute exacerba...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200525060-00005

    authors: Zuin R,Palamidese A,Negrin R,Catozzo L,Scarda A,Balbinot M

    更新日期:2005-01-01 00:00:00

  • Efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological test performance in patients with hepatic cirrhosis : results of a randomised trial.

    abstract:OBJECTIVES:To determine the efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological performance in patients with hepatic cirrhosis and subclinical hepatic encephalopathy (SHE). DESIGN:Randomised, parallel group, controlled trial. PATIENTS AND METHODS:The study enrolled 31 patients with he...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200222001-00002

    authors: Cecere A,Ciaramella F,Tancredi L,Romano C,Gattoni A

    更新日期:2002-11-01 00:00:00

  • Replacement Effects and Budget Impacts of Insurance Coverage for Sodium-Glucose Co-Transporter-2 Inhibitors on Oral Antidiabetic Drug Utilization.

    abstract:BACKGROUND AND OBJECTIVES:A new oral antidiabetic drug class, sodium-glucose co-transporter-2 inhibitors (SGLT-2 inhibitors), has been covered by national health insurance in Taiwan since May 2016. This study estimated the impacts of insurance coverage for SGLT-2 inhibitors on the replacement effects of antidiabetic dr...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0689-2

    authors: Chen HY,Chiu PY,Chang CJ,Tsai LL,Huang YL,Hsu JC

    更新日期:2018-12-01 00:00:00

  • Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies.

    abstract:BACKGROUND AND OBJECTIVES:Dutasteride is currently marketed by GlaxoSmithKline (GSK), either as monotherapy or as a fixed-dose combination with tamsulosin. As part of the project to develop the fixed-dose combination product, alternative formulations of dutasteride were prepared by GSK, and their pharmacokinetic proper...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-016-0419-6

    authors: Fossler M,Zhu J,Roehrborn C,McAleese P,Manyak M

    更新日期:2016-09-01 00:00:00

  • Analgesic efficacy and safety of lornoxicam quick-release formulation compared with diclofenac potassium: randomised, double-blind trial in acute low back pain.

    abstract:BACKGROUND:NSAIDs are widely used for patients presenting with low back pain. A quick-release formulation of lornoxicam, a potent NSAID from the chemical class of oxicams, offers a faster onset of pain relief compared with the standard tablet formulation. METHODS:Time to onset of pain relief with lornoxicam was compar...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00044011-200626050-00004

    authors: Yakhno N,Guekht A,Skoromets A,Spirin N,Strachunskaya E,Ternavsky A,Olsen KJ,Moller PL

    更新日期:2006-01-01 00:00:00

  • Oral Contraceptives and Neutropenia: A Population-Based Cohort Study.

    abstract:BACKGROUND:Oral contraceptives (OCs) are one of the most commonly used classes of drugs worldwide. A case of neutropenia and associated infections in a young woman using OCs that settled after discontinuation and reappeared upon re-challenge, has led us to investigate a potential association between oral contraceptives...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-019-00818-0

    authors: Rosenthal YS,Chodick G,Rosenthal A,Shalev V,Ram HS,Koren G

    更新日期:2019-10-01 00:00:00

  • Preferential Antiseizure Medications in Pediatric Patients with Convulsive Status Epilepticus: A Systematic Review and Network Meta-Analysis.

    abstract:BACKGROUND AND OBJECTIVE:The optimal choice for first- and second-line antiseizure medications for pediatric patients with convulsive status epilepticus remains ambiguous. The present study aimed to estimate the comparative effect on the efficacy and safety of different antiseizure medications in pediatric patients wit...

    journal_title:Clinical drug investigation

    pub_type:

    doi:10.1007/s40261-020-00975-7

    authors: Zhang Y,Liu Y,Liao Q,Liu Z

    更新日期:2021-01-01 00:00:00

  • Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.

    abstract:BACKGROUND AND OBJECTIVES:As compared with individual tablets, saxagliptin/metformin extended-release (XR) fixed-dose combination (FDC) tablets offer potential for increased patient compliance with the convenience of once-daily dosing. Two bioequivalence studies assessed the fed-state bioequivalence of saxagliptin/metf...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/11590290-000000000-00000

    authors: Boulton DW,Smith CH,Li L,Huang J,Tang A,LaCreta FP

    更新日期:2011-01-01 00:00:00

  • Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

    abstract::Page 806, column 1, line 3: The text, which previously read. ...

    journal_title:Clinical drug investigation

    pub_type: 已发布勘误

    doi:10.1007/s40261-020-00892-9

    authors: Lyseng-Williamson KA

    更新日期:2020-03-01 00:00:00

  • Efficacy and Safety of Quinfamide versus Secnidazole in the Management of Amoebic Non-Dysenteric Colitis in Children.

    abstract:OBJECTIVE:To compare the efficacy and safety of single doses of quinfamide and secnidazole in the treatment of amoebic non-dysenteric colitis in children. DESIGN:This was a prospective, longitudinal, double-blind, randomised, comparative study. SETTING:The participants were students or relatives of students at two ur...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200020020-00003

    authors: Padilla N,Díaz R,Muñoz M

    更新日期:2000-01-01 00:00:00

  • Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China.

    abstract:BACKGROUND AND OBJECTIVE:Several antiviral therapies are now available for patients with chronic hepatitis B (CHB), but the most cost-effective strategy for Chinese patients is unclear. The aim of this study was to estimate the long-term cost effectiveness of the antiviral treatments (lamivudine, adefovir, telbivudine ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0273-y

    authors: Zhang C,Ke W,Gao Y,Zhou S,Liu L,Ye X,Yao Z,Yang Y

    更新日期:2015-03-01 00:00:00

  • Massive thrombosis of brachiocephalic veins and superior vena cava syndrome in a patient with non-small cell lung cancer treated with the epidermal growth factor receptor inhibitor erlotinib.

    abstract::The superior vena cava (SVC) syndrome occurs when obstruction of this vessel interrupts venous return of blood from the head, upper extremities and thorax to the right atrium. Most cases of SVC syndrome result from neoplasia, especially from lung cancer, but other non-cancer-associated causes may include fibrosis caus...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200727070-00007

    authors: Salmi R,Gaudenzi P,Di Todaro F,Morandi P,Nielsen I,Manfredini R

    更新日期:2007-01-01 00:00:00

  • Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment.

    abstract:BACKGROUND AND OBJECTIVE:Insulin degludec is a basal insulin with a slow and distinct absorption mechanism resulting in an ultra-long, flat, and stable pharmacokinetic profile in patients with diabetes mellitus. The aim of this study was to examine the effect of hepatic impairment on the single-dose pharmacokinetics of...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-013-0154-1

    authors: Kupčová V,Arold G,Roepstorff C,Højbjerre M,Klim S,Haahr H

    更新日期:2014-02-01 00:00:00

  • Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.

    abstract::The aim of this case study was to examine the efficacy of a dipeptidyl peptidase-4 inhibitor (anagliptin) and an α-glucosidase inhibitor (miglitol) when added to ongoing insulin treatment in patients with type 2 diabetes mellitus. Continuous glucose monitoring was performed in four Japanese insulin-treated inpatients ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-014-0260-8

    authors: Kishimoto M,Noda M

    更新日期:2015-02-01 00:00:00

  • Higher risk of sulfonylurea-associated hypoglycemic symptoms in women with type 2 diabetes mellitus.

    abstract:BACKGROUND:Although some evidence suggests that women may be at greater risk for hypoglycemia, no conclusion has been reached, and female sex has not been taken into account in antidiabetic drug-induced hypoglycemia. This study aimed to determine whether females are at a higher risk of sulfonylurea (SU)-associated hypo...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0314-6

    authors: Kajiwara A,Kita A,Saruwatari J,Oniki K,Morita K,Yamamura M,Murase M,Koda H,Hirota S,Ishizuka T,Nakagawa K

    更新日期:2015-09-01 00:00:00

  • Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm.

    abstract:BACKGROUND AND OBJECTIVE:The skeletal muscle relaxant tizanidine is approved by the US FDA and the European Medicines Agency for treating spasticity and is supplied as tablets for oral administration. However, tizanidine has a poor bioavailability, due to extensive first-pass metabolism. Therefore, the nasal route of a...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-013-0137-2

    authors: Vitale DC,Piazza C,Sinagra T,Urso V,Cardì F,Drago F,Salomone S

    更新日期:2013-12-01 00:00:00

  • Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases.

    abstract::A pharmacokinetic study was carried out in patients with unresectable colorectal liver metastases who had primarily been included in a phase II trial of intra-arterial cisplatin (DDP) plus intravenous fluorouracil. Ten patients of those accrued for the clinical study underwent the pharmacokinetic investigation upon li...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199612020-00005

    authors: Civalleri D,Esposito M,De Cain F,Balletto N,Mondini G,Gogioso L,Viale M,Vannozzi MO

    更新日期:1996-08-01 00:00:00

  • Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study.

    abstract:BACKGROUND AND OBJECTIVE:Hypertension remains a major global health problem, and evidence suggests that the majority of patients will require two or more antihypertensive agents in order to reach specified BP targets. Combining two drugs from different classes has the potential to target different aspects of hypertensi...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00044011-200929070-00001

    authors: Barrios V,Brommer P,Haag U,Calderón A,Escobar C

    更新日期:2009-01-01 00:00:00

  • The Challenge of Pharmacotherapy in Children and Adolescents with Epilepsy-ADHD Comorbidity.

    abstract::Epilepsy is common in children and adolescents where its prevalence is 3.2-5.5/1000. About one-third of patients also have attention deficit hyperactivity/impulsivity disorder (ADHD). The possible relationship between epilepsy and ADHD is still unclear, and ADHD symptoms (such as inattention, hyperactivity, behavioral...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-017-0585-1

    authors: Verrotti A,Moavero R,Panzarino G,Di Paolantonio C,Rizzo R,Curatolo P

    更新日期:2018-01-01 00:00:00

  • Barriers to pain management: focus on opioid therapy.

    abstract::Despite the availability of effective pain treatments, there are numerous barriers to effective management resulting in a large proportion of patients not achieving optimal pain control. Chronic pain is inadequately treated because of a combination of cultural, societal, educational, political and religious constraint...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/11630040-000000000-00000

    authors: Zuccaro SM,Vellucci R,Sarzi-Puttini P,Cherubino P,Labianca R,Fornasari D

    更新日期:2012-02-22 00:00:00

  • Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: a decision-tree analysis.

    abstract:BACKGROUND:Concomitant chemotherapy with radiotherapy is considered to be the standard of care for patients with head and neck cancer and good performance status. However, published reports on the cost effectiveness of this therapeutic approach are extremely rare. OBJECTIVE:The aim of this study was to estimate the co...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11588980-000000000-00000

    authors: Chan AL,Leung HW,Huang SF

    更新日期:2011-10-01 00:00:00

  • Effectiveness and Safety of Amlodipine in Newly Diagnosed Hypertensive Patients and in Previously Diagnosed Hypertensive Patients not Controlled with their Usual Treatment (NOTA Study).

    abstract:OBJECTIVE:To evaluate the effectiveness and safety of amlodipine in two cohorts of hypertensive patients, one newly diagnosed and the other previously diagnosed but not controlled with drug therapy, and to assess the risk factors for the entire sample at the outset of the study. PATIENTS AND DESIGN:We designed a postm...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200323120-00001

    authors: Valcárcel Y,Jiménez R,Arístegui R,Gil A,Nota Study Group.

    更新日期:2003-01-01 00:00:00

  • Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.

    abstract:BACKGROUND AND OBJECTIVES:Dyslipidaemia is a major cardiovascular risk factor associated with type 2 diabetes mellitus. Saroglitazar (ZYH1) is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity. It has been developed for the treatment of dyslipidaemia an...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-013-0128-3

    authors: Jani RH,Kansagra K,Jain MR,Patel H

    更新日期:2013-11-01 00:00:00

  • Clinical experience in invasive fungal infections.

    abstract::Lung infections caused by invasive filamentous fungi are very rare conditions in AIDS, but must be considered in patients with profound immune suppression especially in the presence of additional risk factors, such as hematologic malignancies, corticosteroid therapy, neutropenia, and chemotherapy. The authors report a...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-012-0017-1

    authors: Pacheco P,Ventura AS,Branco T,Gonçalves L,Carvalho C

    更新日期:2013-02-01 00:00:00

  • Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.

    abstract::Doravirine (MK-1439) is a novel non-nucleoside reverse transcriptase inhibitor indicated for the combination treatment of human immunodeficiency virus type-1 (HIV-1) infection. The recommended dose is 100 mg once daily. This review summarizes the pharmacokinetics of doravirine, the influence of intrinsic factors, and ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-020-00934-2

    authors: Khalilieh S,Yee KL,Sanchez R,Stoch SA,Wenning L,Iwamoto M

    更新日期:2020-10-01 00:00:00

  • Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females.

    abstract:OBJECTIVES:This study investigated the pharmacokinetics and pharmacodynamics of a fixed-dose combination (FDC) tablet of olmesartan medoxomil 20 mg and amlodipine 5 mg (CS-8663) in healthy Chinese subjects. METHODS:This single-centre, open-label study was conducted in five healthy males and five females aged 18-45 yea...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-012-0026-0

    authors: Chen X,Hu P,Jiang J,Liu T,Zhong W,Liu H,Zhao Q

    更新日期:2012-12-01 00:00:00